Royalty Pharma (RPRX) reported Q3 net income Wednesday of $544 million, up from $72 million a year earlier.
Comparable analysts' estimates were not available.
Total income and other revenue for the quarter ended Sept. 30 was $565 million, up from $536 million a year earlier.
Three analysts polled by Capital IQ expected $731.8 million.
As of Sept. 30, the company said it had $950 million in cash and cash equivalents.
Royalty Pharma shares were up 3.1% in recent Wednesday premarket activity.
Price: 27.94, Change: +0.84, Percent Change: +3.10
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments